On Oct 19, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $490 to $550.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $550.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $416 to $549.
Evercore analyst Vijay Kumar maintains with a hold rating, and adjusts the target price from $385 to $490.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $475 to $525.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The company's Q3 earnings surpassed expectations, characterized by a 'strong quarter' with significant placements of the Da Vinci 5 system, a surge in procedure volumes, and maintained margin discipline. Additionally, the company's management has revised its FY24 procedure volume growth forecast to a range of 16%-17%, from the previously estimated 15.5%-17%. This adjustment takes into account the potential for a continued decline in bariatric procedures and growing challenges in Asia, such as extended physician strikes in Korea, while also considering a scenario where bariatric procedures stabilize at current rates and the situation in Korea and China does not deteriorate further.
The projection for Intuitive Surgical's revenue outperformance in FY25 appears to be reflected in current market expectations. Following the company's quarterly financial disclosure, it's indicated that the estimate for FY25 earnings per share has been adjusted upward by approximately 3%.
Intuitive Surgical reported robust third-quarter results, outperforming expectations in two crucial aspects - placements of their DV5 systems and growth in procedures. The company is witnessing significant growth momentum following the U.S. approval of the da Vinci 5 system. The early adoption of DV5 is progressing faster than the previous fourth-generation system's launch, with promising signs of potential growth acceleration in the coming years.
The company's Q3 earnings and revenue surpassed expectations, alongside an 18% increase in procedure volume, which also exceeded the consensus forecast by 100 basis points. The expectation is for the growth momentum to persist, especially with the widening array of regulatory clearances for Dv5, anticipating sustained expansion into the latter part of FY25.
The firm has once again raised their expectations, reinforcing their belief in the ongoing potential for growth which supports the company's high valuation. The company is seen as a top-tier long-term growth pick following its performance that surpassed estimates and showed growth acceleration on almost all fronts.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
